ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/MET
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/MET
19
trial(s) found.
NCT06816992
Advanced
Phase 1
Recruiting
Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC (
ORIC-114-05
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
bispecific cMET/EGFR antibody
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06384352
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (
YL211-INT-101-01
)
anti-cMET antibody-drug conjugate
Solid tumour
VIC
3168 - Clayton - Monash Medical Centre
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06082167
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
STELLAR-305
)
MET/VEGFR2/AXL/MER inhibitor
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05987332
Advanced
Phase 2 / Phase 3
Recruiting
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (
IDE196-002
)
ALK inhibitor,first generation
MET inhibitor,type 1
PKC inhibitor
ROS1 inhibitor
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05652868
Advanced
Phase 1
Recruiting
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01 (
MYTX-011-01
)
anti-cMET antibody-drug conjugate
Lung cancer
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
Clear cell renal cell carcinoma
SA
5037 - Glandore - Ashford Cancer Centre
NCT05498428
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer (
PALOMA-2
)
bispecific cMET/EGFR antibody
Non-small cell lung cancer
NCT05261399
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (
SAFFRON
).
EGFR inhibitor,third generation
MET inhibitor,type 1
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (WITHDRAWN)
QLD
4215 - Southport - Gold Coast University Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT04928846
Advanced
Phase 3
Recruiting
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (
M18-868
)
anti-cMET antibody-drug conjugate
taxane
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NCT04830202
Advanced
Available
Expanded Access to Telisotuzumab Vedotin (
C20-503
)
anti-cMET antibody-drug conjugate
Non-small cell lung cancer
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
+ Binimetinib
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06614192
Advanced
Phase 3
Not recruiting
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer (
M24-064
)
Tipiracil Hydrochloride
Trifluridine
anti-VEGF monoclonal antibody
anti-cMET antibody-drug conjugate
antimetabolite
thymidine phosphorylase inhibitor
Colorectal cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06598800
Advanced
Phase 1
Active not recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (
BG-T187-101
)
trispecific EGFR/cMET/cMET antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ MET inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not recruiting (1)
Active not recruiting (1)
Unknown (1)
Status unknown (1)
Recruitment Country and State
VIC (11)
NSW (11)
SA (6)
WA (5)
QLD (4)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 2 / Phase 3 (2)
Phase 3 (5)
Trial Type
Advanced (19)
Cancer Therapy Class
MET
100%
EGFR
32%
PD-1/PD-L1
26%
ROS1
26%
AXL
21%
PD-1
21%
VEGFR2
21%
KIT
21%
VEGFR
21%
ALK
16%
VEGF
11%
MER
11%
PKC
11%
PDGFR
11%
RET
11%
ERBB2
5%
CTLA4
5%
HIF2a
5%
MEK
5%
AR
5%
CYP17A1
5%
PD-L1
5%
androgen axis
5%
ATR
5%
BCR-ABL1
5%
CDK4
5%
CDK6
5%
CRAF
5%
FLT3
5%
JAK1
5%
JAK2
5%
PDGFRA
5%
PI3K
5%
RAF
5%
SMO
5%
SRC
5%
YES1
5%
mTOR
5%
mTORC1
5%
mTORC2
5%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3168 - Clayton - Monash Medical Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
2170 - Liverpool - Liverpool Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
2139 - Concord - Concord Repatriation General Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3181 - Prahran - The Alfred Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4032 - Chermside - The Prince Charles Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Head and neck cancer
Kidney cancer
Urogenital cancer
Colorectal adenocarcinoma
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Oesophageal cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Melanoma
Uveal melanoma
Endocrine gland cancer
Thyroid cancer
Biliary tract cancer
Breast adenocarcinoma
Breast cancer
Epithelial Ovarian Cancer
Exocrine pancreatic cancer
Gynaecological cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Non-clear cell renal cell carcinoma
Clear cell renal cell carcinoma
Cutaneous melanoma
Skin cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Glioblastoma
Glioma
High-grade glioma
MET:alteration
MET:fusion
Malignant glioma
Neurological cancer
Differentiated thyroid carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy